stimotimagene copolymerplasmid

Stimotimagene copolymerplasmid is an investigational anti-tumor gene therapy developed by Gene Surgery LLC for the treatment of solid tumors, including advanced malignant solid neoplasms, anus neoplasms, and breast cancer. It is currently in Phase 1 clinical trials. The therapy utilizes a non-viral gene transfer approach to deliver therapeutic genetic material directly into tumor cells, aiming to stimulate anti-tumor immune responses and inhibit tumor growth. The specific mechanism involves gene transference via a plasmid-copolymer complex; however, the precise genetic payload or target has not been publicly disclosed[1][2][3].